
CYTOSORBENTS CORP
Share · US23283X2062 · CTSO · A12GDU (XNCM)
1,09 USD
10.06.2025 19:59
Current Prices from CYTOSORBENTS CORP
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
CTSO
|
USD
|
10.06.2025 19:59
|
1,09 USD
| 1,04 USD
+4,81 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
4,81 % | 10,10 % | 25,29 % | 6,86 % | 21,43 % | 22,75 % | -88,37 % |
Company Profile for CYTOSORBENTS CORP Share
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Company Data
Name CYTOSORBENTS CORP
Company Cytosorbents Corporation
Symbol CTSO
Website
https://www.cytosorbents.com
Primary Exchange
NASDAQ CAPITAL MARKET
WKN A12GDU
ISIN US23283X2062
Asset Class Share
Sector Healthcare
Industry Medical - Devices
CEO Dr. Phillip P. Chan M.D., Ph.D.
Market Capitalization 64 Mio
Country United States of America
Currency USD
Employees 0,1 T
Address 305 College Road East, 08540 Princeton
IPO Date 2006-08-08
Stock Splits
Date | Split |
---|---|
05.12.2014 | 1:25 |
ID Changes
Date | From | To |
---|---|---|
15.04.2010 | MSBT | CTSO |
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | HQE1.F |
NASDAQ | CTSO |
More Shares
Investors who CYTOSORBENTS CORP hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.